Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo granted FDA approval for three new dosage strengths of Opana ER
The new strengths, 7.5mg, 15mg, and 30mg, will be available on April 1, 2008 and will join previously approved Opana ER dosage strengths of 5mg, 10mg, 20mg, and
The new strengths, 7.5mg, 15mg, and 30mg, will be available on April 1, 2008 and will join previously approved Opana ER dosage strengths of 5mg, 10mg, 20mg, and
The additional indications approved by agency for the oral form of Vasolan will provide a wider range of treatment options for patients who are suffering from tachyarrhythmia. This
Under the terms of the agreement, OneWorld Health, Amyris and sanofi-aventis will work jointly to develop and design pilot and commercial scale manufacturing processes, with the goal of
Data demonstrated that LCP-Tacro has a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf. LCP-Tacro also shows higher bioavailability by more than
The trial is a two-part double-blind, placebo-controlled evaluation of single ascending doses, followed by a crossover multi-dose evaluation in healthy human volunteers. In addition to safety, other objectives
Company will not receive any proceeds from the sale. The offer is expected to close on March 5, 2008. The offering is being made through an underwriting syndicate
In this study safety and tolerability of escalating doses of AZX100 will be evaluated in healthy adult male subjects. A placebo control arm is included in this Phase
Under the terms of the agreement, China Sky One Medical’s wholly-owned subsidiary, Harbin Tian Di Ren Medical Science and Technology Company, will acquire 100% of Tianlong’s operations for
The study has included patients with acute symptoms of schizophrenia who were treated either with Fiapta (iloperidone), a novel atypical antipsychotic agent or placebo. Patients were also studied
The approval is based on results from a four-week, multicenter, randomized, double-blind, placebo-controlled study in pediatric patients (10 to 17 years old) with bipolar I disorder that demonstrated